NCT00864032 Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall Status COMPLETED Phase PHASE1/PHASE2
NCT00863746 A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC). Status COMPLETED Phase PHASE3
NCT00863681 BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension Status COMPLETED Phase PHASE3
NCT00862459 Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) Status COMPLETED Phase PHASE2
NCT00859196 Study to Assess on a Molecular Level the Influence of a 5 % Dexpanthenol Ointment in Subjects With Superficial Injuries Status COMPLETED Phase PHASE4
NCT00858117 A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL Status COMPLETED Phase PHASE2
NCT00855595 Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea Status COMPLETED Phase PHASE4
NCT00855465 A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. Status COMPLETED Phase PHASE3
NCT00855218 A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC). Status COMPLETED Phase PHASE2
NCT00847314 Efficacy and Tolerability of Testogel/Nebido in Combination With Exercise and Diet in Hypogonadal Male Patients Status COMPLETED Phase N/A
NCT00845338 Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity Status TERMINATED Phase PHASE2
NCT00844883 Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma Status COMPLETED Phase PHASE2
NCT00844688 Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC) Status UNKNOWN Phase PHASE2
NCT00839826 ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial Status COMPLETED Phase PHASE2